Glycocalyx as Possible Limiting Factor in COVID-19.
作者信息
Wadowski Patricia P, Jilma Bernd, Kopp Christoph W, Ertl Sebastian, Gremmel Thomas, Koppensteiner Renate
机构信息
Division of Angiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria.
Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria.
出版信息
Front Immunol. 2021 Feb 22;12:607306. doi: 10.3389/fimmu.2021.607306. eCollection 2021.
Abstract
摘要
相似文献
1
Glycocalyx as Possible Limiting Factor in COVID-19.糖萼作为新冠病毒肺炎可能的限制因素
Front Immunol. 2021 Feb 22;12:607306. doi: 10.3389/fimmu.2021.607306. eCollection 2021.
2
Pathogenesis of COVID-19 described through the lens of an undersulfated and degraded epithelial and endothelial glycocalyx.通过欠硫酸化和降解的上皮细胞和内皮细胞糖萼的视角来描述 COVID-19 的发病机制。
FASEB J. 2022 Jan;36(1):e22052. doi: 10.1096/fj.202101100RR.
3
Heparin prevents in vitro glycocalyx shedding induced by plasma from COVID-19 patients.肝素可防止 COVID-19 患者血浆诱导的体外糖萼脱落。
Life Sci. 2021 Jul 1;276:119376. doi: 10.1016/j.lfs.2021.119376. Epub 2021 Mar 27.
4
Endothelial glycocalyx damage as a systemic inflammatory microvascular endotheliopathy in COVID-19.内皮糖萼损伤作为 COVID-19 的全身性炎症性微血管内皮病。
Biomed J. 2020 Oct;43(5):399-413. doi: 10.1016/j.bj.2020.08.007. Epub 2020 Aug 24.
5
Vascular endothelial injury exacerbates coronavirus disease 2019: The role of endothelial glycocalyx protection.血管内皮损伤加重 2019 年冠状病毒病：内皮糖萼保护的作用。
Microcirculation. 2021 Apr;28(3):e12654. doi: 10.1111/micc.12654. Epub 2020 Aug 30.
6
Indications of Persistent Glycocalyx Damage in Convalescent COVID-19 Patients: A Prospective Multicenter Study and Hypothesis.恢复期 COVID-19 患者糖萼持续损伤的指征：一项前瞻性多中心研究和假说。
Viruses. 2021 Nov 21;13(11):2324. doi: 10.3390/v13112324.
7
Protecting the endothelial glycocalyx in COVID-19.在新型冠状病毒肺炎中保护内皮糖萼
PLoS Pathog. 2024 May 16;20(5):e1012203. doi: 10.1371/journal.ppat.1012203. eCollection 2024 May.
8
Graft glycocalyx degradation in human liver transplantation.肝移植中移植物糖萼降解。
PLoS One. 2019 Aug 15;14(8):e0221010. doi: 10.1371/journal.pone.0221010. eCollection 2019.
9
Vascular Endothelial Glycocalyx Damage in COVID-19.新型冠状病毒肺炎中的血管内皮糖萼损伤
Int J Mol Sci. 2020 Dec 19;21(24):9712. doi: 10.3390/ijms21249712.
10
Relevance of Heparan Sulfate and Heparanase to Severity of COVID-19 in the Elderly.硫酸乙酰肝素和乙酰肝素酶与老年人 COVID-19 严重程度的相关性
Semin Thromb Hemost. 2021 Jun;47(4):348-350. doi: 10.1055/s-0040-1722293. Epub 2021 Jan 11.
引用本文的文献
1
Glycocalyx Disintegration Is Associated with Mortality in Chronic Heart Failure.糖萼解体与慢性心力衰竭患者的死亡率相关。
J Clin Med. 2025 May 20;14(10):3571. doi: 10.3390/jcm14103571.
2
Herpesvirus Infection of Endothelial Cells as a Systemic Pathological Axis in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.内皮细胞的疱疹病毒感染作为肌痛性脑脊髓炎/慢性疲劳综合征的一种全身性病理轴
Viruses. 2024 Apr 8;16(4):572. doi: 10.3390/v16040572.
3
Myocardial Oedema as a Consequence of Viral Infection and Persistence-A Narrative Review with Focus on COVID-19 and Post COVID Sequelae.心肌水肿作为病毒感染和持续存在的后果——以 COVID-19 和新冠后遗症为重点的叙述性综述。
Viruses. 2024 Jan 14;16(1):121. doi: 10.3390/v16010121.
4
Micro- and Macrovascular Effects of Inflammation in Peripheral Artery Disease-Pathophysiology and Translational Therapeutic Approaches.外周动脉疾病中炎症的微血管和大血管效应——病理生理学与转化治疗方法
Biomedicines. 2023 Aug 17;11(8):2284. doi: 10.3390/biomedicines11082284.
5
Toll-like Receptors as Pro-Thrombotic Drivers in Viral Infections: A Narrative Review. Toll 样受体在病毒感染中的促血栓形成作用：叙述性综述。
Cells. 2023 Jul 16;12(14):1865. doi: 10.3390/cells12141865.
6
A Case of Autoimmune Small Fiber Neuropathy as Possible Post COVID Sequelae.自身免疫性小纤维神经病一例，可能为新冠后遗症。
Int J Environ Res Public Health. 2023 Mar 10;20(6):4918. doi: 10.3390/ijerph20064918.
7
Microvascular Thrombosis as a Critical Factor in Severe COVID-19.微血管血栓形成是重症 COVID-19 的关键因素。
Int J Mol Sci. 2023 Jan 27;24(3):2492. doi: 10.3390/ijms24032492.
8
Cardiovascular Disease Management in the Context of Global Crisis.全球危机背景下的心血管疾病管理。
Int J Environ Res Public Health. 2022 Dec 30;20(1):689. doi: 10.3390/ijerph20010689.
9
The role of extracellular histones in COVID-19.细胞外组蛋白在 COVID-19 中的作用。
J Intern Med. 2023 Mar;293(3):275-292. doi: 10.1111/joim.13585. Epub 2022 Dec 18.
10
Mineralocorticoid receptor-antagonism prevents COVID-19-dependent glycocalyx damage.醛固酮受体拮抗剂可预防 COVID-19 依赖性糖萼损伤。
Pflugers Arch. 2022 Oct;474(10):1069-1076. doi: 10.1007/s00424-022-02726-3. Epub 2022 Jul 22.
本文引用的文献
1
Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-2 in the United Kingdom, October to November 2020.2020 年 10 月至 11 月英国 SARS-CoV-2 N501Y 突变株的早期传播能力评估。
Euro Surveill. 2021 Jan;26(1). doi: 10.2807/1560-7917.ES.2020.26.1.2002106.
2
Increased Plasma Heparanase Activity in COVID-19 Patients.新型冠状病毒肺炎患者血浆肝素酶活性升高。
Front Immunol. 2020 Oct 6;11:575047. doi: 10.3389/fimmu.2020.575047. eCollection 2020.
3
SARS-CoV-2 Infection Depends on Cellular Heparan Sulfate and ACE2.SARS-CoV-2 感染依赖于细胞表面的肝素硫酸和 ACE2。
Cell. 2020 Nov 12;183(4):1043-1057.e15. doi: 10.1016/j.cell.2020.09.033. Epub 2020 Sep 14.
4
The Glycocalyx and Its Role in Vascular Physiology and Vascular Related Diseases.糖萼及其在血管生理学和血管相关疾病中的作用。
Cardiovasc Eng Technol. 2021 Feb;12(1):37-71. doi: 10.1007/s13239-020-00485-9. Epub 2020 Sep 21.
5
Injury to the Endothelial Glycocalyx in Critically Ill Patients with COVID-19.新型冠状病毒肺炎重症患者的内皮糖萼损伤
Am J Respir Crit Care Med. 2020 Oct 15;202(8):1178-1181. doi: 10.1164/rccm.202007-2676LE.
6
Decreased endothelial glycocalyx thickness is an early predictor of mortality in sepsis.内皮糖萼厚度降低是脓毒症患者死亡率的早期预测指标。
Anaesth Intensive Care. 2020 May;48(3):221-228. doi: 10.1177/0310057X20916471. Epub 2020 Jun 2.
7
Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19.新型冠状病毒肺炎的肺血管内皮细胞炎症、血栓形成和血管生成。
N Engl J Med. 2020 Jul 9;383(2):120-128. doi: 10.1056/NEJMoa2015432. Epub 2020 May 21.
8
Management of acute kidney injury in patients with COVID-19.COVID-19 患者急性肾损伤的管理。
Lancet Respir Med. 2020 Jul;8(7):738-742. doi: 10.1016/S2213-2600(20)30229-0. Epub 2020 May 14.
9
Biological Activities of Rhamnan Sulfate Extract from the Green Algae (Hitoegusa).绿藻（Hitoegusa）岩藻聚糖硫酸酯提取物的生物学活性
Mar Drugs. 2020 Apr 24;18(4):228. doi: 10.3390/md18040228.
10
Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2.使用临床级别的可溶性人血管紧张素转化酶 2 抑制工程化人类组织中的 SARS-CoV-2 感染。
Cell. 2020 May 14;181(4):905-913.e7. doi: 10.1016/j.cell.2020.04.004. Epub 2020 Apr 24.
Zotero 插件